化学
生物利用度
维生素连接蛋白
整合素
药理学
受体
敌手
口服
口服活性
药代动力学
生物化学
体外
医学
作者
Niall A. Anderson,Sébastien Campos,Sharon Butler,Royston C. B. Copley,I. Duncan,Stephen A. Harrison,Joelle Le,Rosemary Maghames,Aleix Pastor-Garcia,John M. Pritchard,James E. Rowedder,Claire Smith,Jack Thomas,Giovanni Vitulli,Simon J. F. Macdonald
标识
DOI:10.1021/acs.jmedchem.9b00962
摘要
The heterodimeric transmembrane αv integrin receptors have recently emerged as potential targets for the treatment of idiopathic pulmonary fibrosis. Herein, we describe how subtle modifications of the central aromatic ring of a series of phenylbutyrate-based antagonists of the vitronectin receptors αvβ3 and αvβ5 significantly change the biological activities against αvβ6 and αvβ8. This resulted in the discovery of a pan αv antagonist (compound 39, 4-40 nM for the integrin receptors named above) possessing excellent oral pharmacokinetic properties in rats (with a clearance of 7.6 mL/(min kg) and a bioavailability of 97%).
科研通智能强力驱动
Strongly Powered by AbleSci AI